COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics (NASDAQ:OSIR) and Genzyme Corp. (NASDAQ:GENZ) today announced the formation of a partnership to address the significant need for effective countermeasures to nuclear terrorism and other radiological emergencies. The initial focus of the partnership will be to develop Prochymal™, a formulation of adult stem cells derived from bone marrow, to treat the potentially lethal complications of acute radiation syndrome (ARS).
